STOCK TITAN

Ginkgo Bioworks Announces Participation in Upcoming Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BOSTON, Feb. 24, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences:

  • Truist Securities AI Symposium - Biotech & Tools on Tuesday, March 1, 2022, at 9:00 a.m. ET
  • Cowen 42nd Annual Health Care Conference 
    • Fireside chat on Tuesday, March 8, 2022, at 2:10 p.m. ET
    • Synthetic Biology Enabling Drug Discovery panel on Tuesday, March 8, 2022, at 3:30 p.m. ET
  • HSBC Build with Bio Conference on Thursday, March 10, 2022, at 8:30 a.m. ET

Further details, webcast links, and replays of the presentations, if available, can be accessed on the company's investor relations website at https://investors.ginkgobioworks.com.

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. For more information, visit https://www.ginkgobioworks.com/.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com

MEDIA CONTACT:

press@ginkgobioworks.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-upcoming-conferences-301489421.html

SOURCE Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Stock Data

1.78B
1.12B
6.74%
83.82%
12.58%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.